<?xml version="1.0" encoding="UTF-8"?>
<p>The potential allosteric inhibitors found in our study were also selected as M
 <sup>pro</sup> inhibitors in several 
 <italic>in silico</italic> studies. In the VS study, cefotiam was found among eight compounds potential SARS-CoV-2 M
 <sup>pro</sup> inhibitors [
 <xref rid="B38-molecules-25-03830" ref-type="bibr">38</xref>]. In another docking study, voriconazole, tobramycin and kanamycin showed potential activity against SARS-CoV-2 M
 <sup>pro</sup> [
 <xref rid="B33-molecules-25-03830" ref-type="bibr">33</xref>,
 <xref rid="B37-molecules-25-03830" ref-type="bibr">37</xref>]. Ospemifene was among 51 hits selected 
 <italic>in silico</italic> against M
 <sup>pro</sup> [
 <xref rid="B39-molecules-25-03830" ref-type="bibr">39</xref>], and propylthiouracil was among the top 20 drugs showing the highest docking score [
 <xref rid="B40-molecules-25-03830" ref-type="bibr">40</xref>]. Besides, we found oseltamivir, the influenza neuraminidase inhibitor, to have a higher docking score against SARS-CoV-2 M
 <sup>pro</sup> than ebselen (
 <xref rid="molecules-25-03830-t002" ref-type="table">Table 2</xref>). The use of oseltamivir was already reported during the COVID-19 epidemic in China, either with or without antibiotics, and clinical trials are ongoing with oseltamivir with multiple combinations with chloroquine and favipiravir [
 <xref rid="B41-molecules-25-03830" ref-type="bibr">41</xref>,
 <xref rid="B42-molecules-25-03830" ref-type="bibr">42</xref>].
</p>
